HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER			PA	TIENT:
Name:			Na	me:
Ward:			NH	lt
Гalig	luce	eras	se alfa	
	ssess	smen	nt required after 12 months (tick boxes where appropriate)	
and		Prescribed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.		
	and		The patient has a diagnosis of symptomatic type 1 or type 3* Gauc of glucocerebrosidase in leukocytes or cultured skin fibroblasts, an	
	and	0	Patient does not have another life-threatening or severe disease w replacement therapy (ERT) or the disease might be reasonably ex	
		or	O Patient has haematological complications of Gaucher diseas	se e
		or		
		or	Patient has significant liver dysfunction or hepatomegaly attr	
		or		nificant decrease in percentile linear growth over a 6-12 month
	and	Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units)		
Note	Indi	icatio	on marked with * is an unapproved indication	
	ssess equis	smen sites Preso	nt required after 3 years (tick boxes where appropriate) cribed by, or recommended by a metabolic physician or any relevant ordance with a protocol or guideline that has been endorsed by the H	
	and		Patient has demonstrated a symptomatic improvement and has matherapy was started	aintained improvements in the main symptom or symptoms for which
	and	\circ	Patient has demonstrated a clinically objective improvement or no spleen size	deterioration in haemoglobin levels, platelet counts and liver and
	and and		RRadiological (MRI) signs of bone activity performed at two years no deterioration shown by the MRI, compared with MRI taken imm	since initiation of treatment, and five yearly thereafter, demonstrate ediately prior to commencement of therapy or adjusted dose
			Patient has not developed another medical condition that might rea	asonably be expected to compromise a response to ERT
		0	Patient is adherent with regular treatment and taliglucerase alfa is week rounded to the nearest whole vial (200 units)	to be administered at a dose no greater than 30 unit/kg every other